Literature DB >> 26253555

Guidelines for the management of Helicobacter pylori infection in Italy: The III Working Group Consensus Report 2015.

Rocco Maurizio Zagari1, Marco Romano2, Veronica Ojetti3, Reinhold Stockbrugger4, Sergio Gullini5, Bruno Annibale6, Fabio Farinati7, Enzo Ierardi8, Giovanni Maconi9, Massimo Rugge10, Carlo Calabrese11, Francesco Di Mario12, Francesco Luzza13, Stefano Pretolani14, Antonella Savio15, Giovanni Gasbarrini3, Michele Caselli5.   

Abstract

Knowledge on the role of Helicobacter pylori (HP) infection is continually evolving, and treatment is becoming more challenging due to increasing bacterial resistance. Since the management of HP infection is changing, an update of the national Italian guidelines delivered in 2007 was needed. In the III Working Group Consensus Report 2015, a panel of 17 experts from several Italian regions reviewed current evidence on different topics relating to HP infection. Four working groups examined the following topics: (1) "open questions" on HP diagnosis and treatment (focusing on dyspepsia, gastro-oesophageal reflux disease, non-steroidal anti-inflammatory drugs or aspirin use and extra-gastric diseases); (2) non-invasive and invasive diagnostic tests; (3) treatment of HP infection; (4) role of HP in the prevention of gastric cancer. Statements and recommendations were discussed and a consensus reached in a final plenary session held in February 2015 in Bologna. Recommendations are based on the best current evidence to help physicians manage HP infection in Italy. The guidelines have been endorsed by the Italian Society of Gastroenterology and the Italian Society of Digestive Endoscopy.
Copyright © 2015 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Guidelines; Helicobacter pylori; Italy; Management

Mesh:

Substances:

Year:  2015        PMID: 26253555     DOI: 10.1016/j.dld.2015.06.010

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  30 in total

1.  Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: how should rifabutin be managed in rescue regimens?

Authors:  Giuseppe Losurdo; Andrea Iannone; Floriana Giorgio; Mariabeatrice Principi; Alfredo Di Leo; Enzo Ierardi
Journal:  United European Gastroenterol J       Date:  2015-12-15       Impact factor: 4.623

2.  Adherence to international guidelines for the management of Helicobacter pylori infection among gastroenterologists and gastroenterology fellows in Italy: A Survey of the Italian Federation of Digestive Diseases - FISMAD.

Authors:  Rocco Maurizio Zagari; Marco Romano; Leonardo Frazzoni; Giovanni Marasco; Elton Dajti; Paolo Giorgio Arcidiacono; Alessandro Armuzzi; Federico Biagi; Renato Cannizzaro; Giulia Martina Cavestro; Carolina Ciacci; Fabio Monica; Sergio Peralta; Franco Radaelli; Franco Bazzoli
Journal:  Helicobacter       Date:  2021-11-11       Impact factor: 5.182

3.  Role of concomitant therapy for Helicobacter pylori eradication: A technical note.

Authors:  Giuseppe Losurdo; Floriana Giorgio; Andrea Iannone; Mariabeatrice Principi; Michele Barone; Alfredo Di Leo; Enzo Ierardi
Journal:  World J Gastroenterol       Date:  2016-10-14       Impact factor: 5.742

4.  Response to: Comment on "Efficacy of 7-Day and 14-Day Triple Therapy Regimens for the Eradication of Helicobacter pylori: A Comparative Study in a Cohort of Romanian Patients".

Authors:  Davide Giuseppe Ribaldone; Giorgio Saracco; Rinaldo Pellicano
Journal:  Gastroenterol Res Pract       Date:  2016-08-24       Impact factor: 2.260

Review 5.  Probiotic monotherapy and Helicobacter pylori eradication: A systematic review with pooled-data analysis.

Authors:  Giuseppe Losurdo; Rossella Cubisino; Michele Barone; Mariabeatrice Principi; Gioacchino Leandro; Enzo Ierardi; Alfredo Di Leo
Journal:  World J Gastroenterol       Date:  2018-01-07       Impact factor: 5.742

6.  Rescue Therapies for H. pylori Infection in Italy.

Authors:  Vincenzo De Francesco; Angelo Zullo; Luigi Gatta; Raffaele Manta; Matteo Pavoni; Ilaria Maria Saracino; Giulia Fiorini; Dino Vaira
Journal:  Antibiotics (Basel)       Date:  2021-05-03

7.  Performance evaluation of a rapid whole-blood immunoassay for the detection of IgG antibodies against Helicobacter pylori in daily clinical practice.

Authors:  Dietmar Enko; Gabriele Halwachs-Baumann; Robert Stolba; Ortrun Rössler; Gernot Kriegshäuser
Journal:  Ann Clin Microbiol Antimicrob       Date:  2016-08-08       Impact factor: 3.944

Review 8.  Gastric mucosa-associated lymphoid tissue lymphoma and Helicobacter pylori infection: a review of current diagnosis and management.

Authors:  Qinglong Hu; Yizhuo Zhang; Xiaoyan Zhang; Kai Fu
Journal:  Biomark Res       Date:  2016-07-27

Review 9.  Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression.

Authors:  Carmelo Scarpignato; Luigi Gatta; Angelo Zullo; Corrado Blandizzi
Journal:  BMC Med       Date:  2016-11-09       Impact factor: 8.775

10.  Dose-dependent association of proton pump inhibitors use with gastric intestinal metaplasia among Helicobacter pylori-positive patients.

Authors:  Yifat Snir; Haim Leibovitzh; Yaara Leibovici-Weissman; Alex Vilkin; Arnon D Cohen; Tzippy Shochat; Yaron Niv; Iris Dotan; Ilan Feldhamer; Doron Boltin; Zohar Levi
Journal:  United European Gastroenterol J       Date:  2021-03-18       Impact factor: 4.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.